AMPK-α is an important target for therapeutic intervention of GLD; AMPK-α and its downstream regulatory factors such as SREBP-1c, FAS, ACC, and SCD1 regulate glucose and lipid metabolism [37, 38]. Here, SREBF1 is linked to Krabbe disease.